- •Venous thromboembolism (VTE) is a common event among autoimmune diseases.
- •Recurrent VTE is known to be increased on these patients after treatment discontinuation.
- •VTE treatment duration in autoimmune diseases is currently on investigation.
- •Randomized trials are lacking and observational registries provide the best available evidence so far.
- Autoimmune disorders and venous thromboembolism: an update from the COMMAND VTE registry.Eur J Intern Med. 2021; 84: 106-108
- Venous thromboembolism in patients with autoimmune disorders: findings from the RIETE registry [published correction appears in Angiology. 2020 May;71(5):482].Angiology. 2020; 71: 131-138
- Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry.Br J Haematol. 2021; 194: 195-199
- Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.Thromb Res. 2013; 131: 24-30
- The 2019 ESC guidelines on the diagnosis and man- agement of acute pulmonary embolism.Eur Heart J. 2019; 40: 3453-3455
- Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset.J Rheumatol. 2009; 36: 68-75
- Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.Ann Rheum Dis. 2021; 80: 169-175
- Immunosuppressants reduce venous thrombosis relapse in Behçet's disease.Arthritis Rheum. 2012; 64: 2753-2760
- Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.Lancet. 2010; 375: 657-663